Eli Lilly to Acquire Merida Biosciences for Up to $2.88 Billion, Adding Novel Autoantibody-Targeting Pipeline
核心洞察
Eli Lilly agreed to acquire privately held Merida Biosciences (搜索) for up to $2.88 billion in cash, with the transaction expected to close in the fourth quarter.
The deal centers on lead candidate MER511 (搜索), designed to block autoantibody binding to thyroid-stimulating hormone receptors for Graves' disease (搜索) and thyroid eye disease (搜索).
Preliminary phase 1 data showed MER511 (搜索) substantially lowered thyroid-stimulating antibodies linked to the diseases while demonstrating a favorable initial safety profile.
Eli Lilly has continued its lengthy streak of acquisitions in 2026 with a $2.88 billion agreement to buy immunology and inflammation specialist Merida Biosciences (搜索), a privately held company based in Cambridge, Massachusetts. The deal, announced on Monday, will give Lilly rights to a pipeline of therapies headed by MER511 (搜索) for Graves' disease (搜索) and thyroid eye disease (搜索) (TED), both autoimmune diseases leading to an overactive thyroid gland.
Lilly is paying up to $2.875 billion in cash for Merida, including an undisclosed upfront payment and contingent milestone payments, and expects the takeover to complete in the fourth quarter.
A Precision Approach to Antibody-Driven Disease
MER511 (搜索) is designed to block the binding of autoantibodies to thyroid-stimulating hormone receptors (TSHR). The drug has generated preliminary phase 1 clinical data that back up its proposed mechanism of action and point to a promising safety profile. Lilly said initial data showed MER511 substantially lowered the thyroid-stimulating antibodies linked to the diseases, while showing a favorable initial safety profile.
"We're building our pipeline around therapies that meaningfully change the course of disease, not just its downstream effects," said Francisco Ramírez-Valle, head of Lilly's immunology R&D division and senior vice president of immunology research and early clinical development. "Merida's lead program is designed to do exactly that."
Ramírez-Valle added: "We see potential to apply this precision approach across a broad range of antibody-driven diseases, and we look forward to advancing this novel technology working with the Merida team."
Disease Burden and Current Treatment Landscape
Graves' disease (搜索) causes the thyroid to become overactive and leads to weight loss, irritability, and fatigue, while TED is a related condition characterised by swelling of the muscles and fat tissue behind the eyes, leading to proptosis, where the eyeball moves forward. Up to 40% of patients with Graves' disease will also develop TED.
Treatments for Graves' disease (搜索) currently include antithyroid medications, radioactive iodine and surgery, while there are two FDA-approved medicines for thyroid eye disease (搜索): Amgen's Tepezza and Viridian Therapeutics' Lumvoa (搜索).
A Broader Pipeline Targeting Pathogenic Autoantibodies
Other programmes at Merida are focused on allergy and primary membranous nephropathy, a chronic autoimmune disease that affects the kidneys, and are also targeted at pathogenic autoantibodies. Its second candidate, MER769 (搜索), is in preclinical testing and is being developed for food allergy, asthma, and chronic spontaneous urticaria (CSU). Merida is developing medicines to selectively target antibodies that cause a range of immunity-related conditions.
Lilly's Expanding Acquisition Strategy
Lilly has been spending freely in business development in the last few quarters, with additions to its pipeline fuelled by cash generated by its fast-growing tirzepatide-based therapies — Mounjaro and Zepbound — for type 2 diabetes and obesity. The new acquisition is Lilly's ninth since the start of the year, coming just a few weeks after it agreed to buy psychedelic medicines developer AtaiBeckley for up to $3.8 billion. Its spending on M&A is now approaching $29 billion in upfront and milestone payments.
Prior acquisitions include a trio of companies in the infectious diseases arena, obesity and diabetes drug developer Kelonia, sleep disorder specialist Centessa Pharma, in vivo CAR-T therapy developer Orna Therapeutics, and immunology-focused Ventyx Bio.